Headlines about Inotek Pharmaceuticals (NASDAQ:ITEK) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Inotek Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.4576664808371 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, Zacks Investment Research lowered shares of Inotek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th.
Shares of Inotek Pharmaceuticals (NASDAQ ITEK) traded down $0.06 on Tuesday, reaching $2.28. 272,300 shares of the company’s stock traded hands, compared to its average volume of 1,110,130. The company has a quick ratio of 27.63, a current ratio of 27.63 and a debt-to-equity ratio of 0.97. Inotek Pharmaceuticals has a twelve month low of $0.85 and a twelve month high of $7.40.
About Inotek Pharmaceuticals
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.